Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Nov 7, 2024
– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting –
Read more at globenewswire.com1.36
+0.16 (+13.33%)
Find more stocks in the Stock Screener
HOWL Latest News and Analysis
14 days ago - ChartmillTop movers in Tuesday's after hours sessionAs the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
